Eric K. Singhi, Thoracic Medical Oncologist at MD Anderson Cancer Center, shared a post on X:
“U.S. FDA approves taletrectinib for ROS1+ mNSCLC.
Treatment-naïve:
– ORR: 90% (TRUST-I), 85% (TRUST-II)
– DOR ≥12 mo: 72%, 63%TKI-pretreated:
– ORR: 52% (TRUST-I), 62% (TRUST-II)
– DOR ≥6 mo: 74%, 83%Liver tox, ILD/pneumonitis, QTc, hyperuricemia, myalgia, fractures.”
More posts featuring Eric Singhi on OncoDaily.